Elekta (OTCMKTS:EKTAY) Sees Strong Trading Volume – What’s Next?
by Amy Steele · The Cerbat GemElekta AB (OTCMKTS:EKTAY – Get Free Report) shares saw unusually-high trading volume on Wednesday . Approximately 1,069 shares changed hands during mid-day trading, an increase of 328% from the previous session’s volume of 250 shares.The stock last traded at $6.27 and had previously closed at $6.15.
Analyst Upgrades and Downgrades
Separately, Zacks Research raised shares of Elekta from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 16th. Three research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Elekta has a consensus rating of “Reduce”.
Read Our Latest Research Report on EKTAY
Elekta Trading Up 3.0%
The company has a quick ratio of 0.79, a current ratio of 1.04 and a debt-to-equity ratio of 0.66. The company’s fifty day moving average price is $5.47 and its two-hundred day moving average price is $5.19. The firm has a market cap of $2.31 billion, a PE ratio of 89.66 and a beta of 1.04.
Elekta (OTCMKTS:EKTAY – Get Free Report) last posted its quarterly earnings results on Wednesday, November 26th. The company reported $0.07 earnings per share (EPS) for the quarter. Elekta had a net margin of 1.62% and a return on equity of 12.14%. The firm had revenue of $427.85 million during the quarter, compared to analysts’ expectations of $436.91 million. As a group, sell-side analysts forecast that Elekta AB will post 0.36 earnings per share for the current fiscal year.
About Elekta
Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.
The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.